

Suuren valiokunnan mietintö n:o 92 hallituksen esityksen johdosta laiksi julkisesta notaarista annetun lain 1 §:n muuttamisesta

Suuri valiokunta on, käsiteltyään edellä mainitun asian, päättänyt yhtyä kannattamaan toisen lakivaliokunnan mietinnössä n:o 6 tehtyä ehdotusta ja ehdottaa siis kunnioittaen,

että Eduskunta päättäisi hyväksyä hallituksen esitykseen sisältyvän lakiehdotuksen muuttamattomana.

Helsingissä 9 päivänä kesäkuuta 1982

The first step in the process of identifying a potential target for a new drug is to identify a target that is involved in the disease process. This can be done by looking at the genes and proteins that are involved in the disease process. One way to do this is to look at the genes that are up-regulated or down-regulated in the disease state. Another way is to look at the proteins that are involved in the disease process. Once a target has been identified, the next step is to develop a drug that can target the target. This can be done by using a variety of methods, including high-throughput screening, rational drug design, and combinatorial chemistry. Once a drug has been developed, the next step is to test it in preclinical studies to determine its safety and efficacy. If the drug is found to be safe and effective, it can then be tested in clinical trials to determine its safety and efficacy in humans.

bioRxiv preprint doi: <https://doi.org/10.1101/000000>; this version posted May 1, 2013. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license.

bioRxiv